N/A
Completed N=3,331
Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Measles/Rubella
Source: ClinicalTrials.gov NCT02158364 ↗
Enrolled (actual)
3,331
Serious AEs
0.1%
Results posted
Jan 2018
Primary outcomePrimary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Summary
The purpose of this survey is to assess the safety of freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) (freeze-dried live attenuated measles and rubella combined vaccine "Takeda") in terms of the occurrence of unknown/known adverse drug reactions and factors that may influence the safety of vaccinees after the second vaccination.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Serious Adverse Drug Reactions (ADRs) |
2 | — |
| SECONDARY Number of Participants With Adverse Drug Reactions (ADRs) |
590 | — |
Eligibility Criteria
Inclusion Criteria
-
Vaccinees who meet both of the following conditions [1] and [2]:
- Vaccinees who have a prior history of receiving measles and/or rubella vaccination and who received freeze-dried live attenuated measles and rubella combined vaccine "Takeda" as the second vaccination
- Vaccinees whose guardians are able to participate in a questionnaire survey on the health status of vaccinees after vaccination with freeze-dried live attenuated measles and rubella combined vaccine "Takeda"
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT02158364). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.